Sign In
Buy MRTX
$58.70
+0 (+0%)
At Close: Apr 19, 2024
Mirati (MRTX) Beats on Q3 Earnings, Begins NDA Adagrasib Filing
12:14pm, Tuesday, 09'th Nov 2021
Mirati's (MRTX) third-quarter earnings beat estimates. It initiates the NDA submission for adagrasib in second-line NSCLC.
Mirati Posts More Responses For Adagrasib-Keytruda Combo In Lung Cancer Setting
07:44am, Tuesday, 09'th Nov 2021
In its Q3 earnings release, Mirati Therapeutics Inc (NASDAQ: MRTX) posted preliminary results from the Phase 1b cohort of the KRYSTAL-1 study evaluating adagrasib plus Merck & Co Inc's (NYSE: MRK
Mirati Therapeutics, Inc. (MRTX) CEO David Meek on Q3 2021 Results - Earnings Call Transcript
10:24pm, Monday, 08'th Nov 2021
Mirati Therapeutics, Inc. (MRTX) CEO David Meek on Q3 2021 Results - Earnings Call Transcript
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates
07:09pm, Monday, 08'th Nov 2021
Mirati (MRTX) delivered earnings and revenue surprises of 45.99% and 91.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Mirati: Running On Good Science And A Lot Of Enthusiasm
06:54am, Monday, 08'th Nov 2021
Mirati: Running On Good Science And A Lot Of Enthusiasm
Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and Recent Corporate Updates on November 8, 2021
04:30pm, Monday, 01'st Nov 2021
SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2021 and recent c
Mirati Therapeutics COO, CMO Exit, Completing Management Overhaul
11:57am, Monday, 01'st Nov 2021
Shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) are retreating sharply Monday following two executive departures. What Happened: Mirati, a clinical-stage targeted oncology company, said its Chief O
SAN DIEGO, Oct. 7, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement with Sano
Biogen, Mirati and Arcturus Reportedly on Merck's Radar
03:39pm, Thursday, 07'th Oct 2021
Even after recently agreeing to shell out $11.5 billion to acquire Acceleron Pharma Inc. ( XLRN , Financial), Merck & Co. Inc. ( MRK , Financial) says it's not done in its quest for deals aimed at div
SAN DIEGO, Oct. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced new clinical and preclinical research will be presented
Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study
12:59pm, Monday, 20'th Sep 2021
Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.
New CEO At Mirati Therapeutics
09:45am, Monday, 20'th Sep 2021
Amid data readouts from adagrasib, sitravatinib programs, Mirati Therapeutics Inc (NASDAQ: MRTX) has appointed David Meek as Chief Executive Officer, effective immediately. Related: Mirati Po
Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
09:38am, Monday, 20'th Sep 2021
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500 of sitravatinib combined with Bristol-Myers Squibb Co's (NYSE: B
Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards
09:19am, Monday, 20'th Sep 2021
After data readout from KRAS drug adagrasib in colon cancer, Mirati Therapeutics Inc (NASDAQ: MRTX) has announced positive topline results from a Phase II cohort of its KRYSTAL-1 study of adagras
Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO
09:12am, Monday, 20'th Sep 2021
Mirati Therapeutics Inc (NASDAQ: MRTX) announced results from the 600mg BID dose cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib in heavily pretreated colorectal cancer patients harb
